MYOS Signs Extension Of Supply Agreement For Fortetropin

(RTTNews) - MYOS Corp. (MYOS), an emerging biotherapeutics and bionutrition company, Friday said it has signed an extension of its supply agreement with Deutsches Institut fuer Lebensmitteltechnik e.V or DIL, the German Institute for Food Technologies, for the continued manufacturing and supply of Fortetropin, the first clinically proven natural myostatin inhibitor.

DIL is a world leader in developing and providing fine products in food technology.

Under the terms of the agreement, DIL will manufacture and supply Fortetropin exclusively for MYOS through the end of 2016 with a significant cost-savings component.

The supply relationship maintains the stable, world-class manufacturing and supply of Fortetropin, the primary proprietary ingredient in MYOS' core muscle health bionutrition supplement products.